235 related articles for article (PubMed ID: 17515522)
1. Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis.
Demierre MF; Ferzli P; Miller D
Arch Dermatol; 2007 May; 143(5):659-61. PubMed ID: 17515522
[No Abstract] [Full Text] [Related]
2. Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.
Sepmeyer JA; Greer JP; Koyama T; Zic JA
J Am Acad Dermatol; 2007 Apr; 56(4):584-7. PubMed ID: 17184879
[TBL] [Abstract][Full Text] [Related]
3. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
French LE; Shapiro M; Junkins-Hopkins JM; Vittorio CC; Rook AH
J Am Acad Dermatol; 2001 Dec; 45(6):914-8. PubMed ID: 11712039
[TBL] [Abstract][Full Text] [Related]
4. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
[TBL] [Abstract][Full Text] [Related]
5. A case of poikiloderma vasculare atrophicans, a rare variant of cutaneous T-cell lymphoma, responding to extracorporeal photopheresis.
Kreuter A; Hoffmamm K; Altmeyer P
J Am Acad Dermatol; 2005 Apr; 52(4):706-8. PubMed ID: 15793532
[No Abstract] [Full Text] [Related]
6. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
[No Abstract] [Full Text] [Related]
7. Bexarotene: new preparation. Cutaneous lymphoma: too many adverse effects.
Prescrire Int; 2004 Jun; 13(71):94-7. PubMed ID: 15233146
[TBL] [Abstract][Full Text] [Related]
8. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey.
Demierre MF; Gan S; Jones J; Miller DR
Cancer; 2006 Nov; 107(10):2504-11. PubMed ID: 17048251
[TBL] [Abstract][Full Text] [Related]
9. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
10. [Extracorporeal photopheresis in dermatology].
Pérez-Carmona L; Harto-Castaño A; Díez-Recio E; Jaén-Olasolo P
Actas Dermosifiliogr; 2009; 100(6):459-71. PubMed ID: 19709550
[TBL] [Abstract][Full Text] [Related]
11. Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.
Bisaccia E; Vonderheid EC; Geskin L
Br J Dermatol; 2009 Jul; 161(1):167-9. PubMed ID: 19298276
[TBL] [Abstract][Full Text] [Related]
12. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
13. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
McGinnis KS; Junkins-Hopkins JM; Crawford G; Shapiro M; Rook AH; Vittorio CC
J Am Acad Dermatol; 2004 Mar; 50(3):375-9. PubMed ID: 14988678
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what?
Dummer R; Assaf C; Bagot M; Gniadecki R; Hauschild A; Knobler R; Ranki A; Stadler R; Whittaker S
Eur J Cancer; 2007 Nov; 43(16):2321-9. PubMed ID: 17707638
[TBL] [Abstract][Full Text] [Related]
15. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
Ferenczi K; Yawalkar N; Jones D; Kupper TS
Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
[TBL] [Abstract][Full Text] [Related]
17. Treatment of cutaneous T-cell lymphoma: an update.
Young JW
J Am Osteopath Assoc; 1993 May; 93(5):591-8, 603. PubMed ID: 8314721
[TBL] [Abstract][Full Text] [Related]
18. Small-scale extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: a report of 3 cases.
Schreiner T; Gaczkowski A; Scharffetter-Kochanek K; Borberg H
Transfus Apher Sci; 2005 Apr; 32(2):197-203. PubMed ID: 15784454
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
20. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
Shapiro M; Rook AH; Lehrer MS; Junkins-Hopkins JM; French LE; Vittorio CC
J Am Acad Dermatol; 2002 Dec; 47(6):956-61. PubMed ID: 12451388
[No Abstract] [Full Text] [Related]
[Next] [New Search]